Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Haddad

Showing results (591-600 of 698) with videos related to

Pageof 70
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|August 5, 2015
Endothelin receptor B, a candidate gene from human studies at high altitude, improves cardiac tolerance to hypoxia in genetically engineered heterozygote miceTsering Stobdan, Dan Zhou, Eilleen Ao-Ieong, et al.
Molecules (Basel, Switzerland)|May 21, 2020
The Geraniin-Rich Extract from Reunion Island Endemic Medicinal Plant <i>Phyllanthus phillyreifolius</i> Inhibits Zika and Dengue Virus Infection at Non-Toxic Effect Doses in ZebrafishJuliano G Haddad, Dovilė Grauzdytė, Andrea Cristine Koishi, et al.
Hemoglobin|July 18, 2014
Preventing thalassemia in Lebanon: successes and challenges in a developing countryMichele Abi Saad, Anthony G Haddad, Elie S Alam, et al.
Translational Gastroenterology and Hepatology|May 17, 2023
Clinical outcomes: endoscopic resection of duodenal ampullary lesionsStephanie M Woo, Mark J Real, Brett M Will, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 26, 2011
Experimental selection of hypoxia-tolerant Drosophila melanogasterDan Zhou, Nitin Udpa, Merril Gersten, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 12, 2023
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up ResultsGeorgina Gener-Ricos, Fadi G Haddad, Koji Sasaki, et al.
Frontiers in Pharmacology|June 19, 2023
Corrigendum: Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptorLaura Grohs, Linhan Cheng, Saskia Cönen, et al.
Frontiers in Physiology|April 26, 2021
Influence of Intermittent Hypoxia/Hypercapnia on Atherosclerosis, Gut Microbiome, and MetabolomeJin Xue, Celeste Allaband, Dan Zhou, et al.
Frontiers in Pharmacology|April 3, 2023
Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptorLaura Grohs, Linhan Cheng, Saskia Cönen, et al.
Cancer|May 28, 2024
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phaseFadi G Haddad, Koji Sasaki, Lewis Nasr, et al.
Pageof 70

Showing results (591-600 of 698) with videos related to

Sort By:
Pageof 70
Proceedings of the National Academy of Sciences of the United States of America|August 5, 2015
Endothelin receptor B, a candidate gene from human studies at high altitude, improves cardiac tolerance to hypoxia in genetically engineered heterozygote miceTsering Stobdan, Dan Zhou, Eilleen Ao-Ieong, et al.
Molecules (Basel, Switzerland)|May 21, 2020
The Geraniin-Rich Extract from Reunion Island Endemic Medicinal Plant <i>Phyllanthus phillyreifolius</i> Inhibits Zika and Dengue Virus Infection at Non-Toxic Effect Doses in ZebrafishJuliano G Haddad, Dovilė Grauzdytė, Andrea Cristine Koishi, et al.
Hemoglobin|July 18, 2014
Preventing thalassemia in Lebanon: successes and challenges in a developing countryMichele Abi Saad, Anthony G Haddad, Elie S Alam, et al.
Translational Gastroenterology and Hepatology|May 17, 2023
Clinical outcomes: endoscopic resection of duodenal ampullary lesionsStephanie M Woo, Mark J Real, Brett M Will, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 26, 2011
Experimental selection of hypoxia-tolerant Drosophila melanogasterDan Zhou, Nitin Udpa, Merril Gersten, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 12, 2023
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up ResultsGeorgina Gener-Ricos, Fadi G Haddad, Koji Sasaki, et al.
Frontiers in Pharmacology|June 19, 2023
Corrigendum: Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptorLaura Grohs, Linhan Cheng, Saskia Cönen, et al.
Frontiers in Physiology|April 26, 2021
Influence of Intermittent Hypoxia/Hypercapnia on Atherosclerosis, Gut Microbiome, and MetabolomeJin Xue, Celeste Allaband, Dan Zhou, et al.
Frontiers in Pharmacology|April 3, 2023
Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptorLaura Grohs, Linhan Cheng, Saskia Cönen, et al.
Cancer|May 28, 2024
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phaseFadi G Haddad, Koji Sasaki, Lewis Nasr, et al.
Pageof 70